China Approves First Targeted Vitiligo Drug, Offering Hope to Millions

SHENZHEN, CHINA – January 30, 2026 – China's National Medical Products Administration (NMPA) has officially approved ruxolitinib phosphate cream, marking a watershed moment for the more than 10 million people in the country living with vitiligo. The decision, announced today, makes the cream the first and only targeted therapy for the chronic autoimmune skin condition to be sanctioned in China, addressing a profound unmet medical need.

The approval was granted to Dermavon Holdings Limited, a subsidiary of China Medical System Holdings Limited (CMS), for the treatment of non-segmental vitiligo with facial involvement in adult and adolescent patients aged 12 years and older. This milestone is not only a medical breakthrough but also a testament to China's evolving regulatory landscape, which is increasingly focused on accelerating patient access to innovative global medicines.

A New Dawn for Patient Care

Vitiligo is a disease characterized by the loss of pigment-producing cells, or melanocytes, resulting in discolored patches of skin. While not life-threatening, its visible nature can cause significant psychological distress and social stigma, severely impacting quality of life. In China, where an estimated 10.3 million people are affected, treatment options have historically been limited to topical corticosteroids and calcineurin inhibitors, which come with potential long-term side effects and often yield unsatisfactory results.

The approval of ruxolitinib phosphate cream, a selective JAK1/JAK2 inhibitor developed by Incyte and marketed as Opzelura® in the U.S. and Europe, introduces a new paradigm. The cream works by targeting the specific inflammatory pathways that drive the depigmentation process. Its efficacy was validated in two pivotal Phase III global studies, TRuE-V1 and TRuE-V2. In both trials, nearly 30% of patients treated with the cream achieved at least a 75% improvement in the Facial Vitiligo Area Scoring Index (F-VASI 75) after 24 weeks, a result significantly superior to placebo. Critically, repigmentation continued to improve with sustained use over 52 weeks.

Long before today's formal approval, the drug's potential was already being realized in China. Thanks to innovative regulatory pathways, the cream was made available to over 7,000 patients through pilot programs. A real-world study conducted in China's Lecheng Pilot Zone in Hainan confirmed the positive results seen in global trials and, importantly, identified no new safety concerns. This early access has already provided tangible hope and results for a community long underserved by existing therapies.

A Strategic Triumph Bolstering an IPO

The approval is a major strategic victory for CMS and its dermatology-focused subsidiary, Dermavon. CMS secured the exclusive rights to develop and commercialize ruxolitinib phosphate cream in Greater China and eleven Southeast Asian countries through a licensing agreement with Incyte in December 2022. This move positioned the company to tap into a substantial market opportunity; China's vitiligo treatment market was valued at over USD 170 million in 2024 and is projected to see steady growth.

This landmark approval is particularly timely for Dermavon, which is currently pursuing a separate listing on the Hong Kong Stock Exchange. Possessing the sole targeted therapy for vitiligo in a market of over 10 million patients significantly enhances Dermavon's portfolio and market position, likely bolstering its valuation ahead of the planned IPO. The new product is expected to create powerful synergies with Dermavon's existing commercialized assets, such as the psoriasis treatment ILUMETRI and the exclusive cream Hirudoid, strengthening its network and resources within the competitive skin health sector.

Industry analysts see this as a textbook example of successfully navigating the pharmaceutical landscape. By licensing a best-in-class asset and skillfully leveraging domestic regulatory channels, CMS has not only addressed a critical health need but also created significant commercial value that will underpin Dermavon's future growth.

China's Regulatory Fast Track in Action

The story of ruxolitinib phosphate cream's journey to market in China is also a story of the country's successful regulatory reforms. The approval was significantly accelerated by forward-thinking policies designed to bring innovative treatments to Chinese patients faster than ever before.

Key among these were the “Early and Pilot Implementation” policies granted to the Hainan Free Trade Port and its Lecheng Pilot Zone. These initiatives create a special channel for using drugs and medical devices that are approved overseas but not yet in China, allowing for crucial real-world data collection on Chinese patients. This data, which demonstrated the cream's safety and efficacy, was instrumental in supporting the formal NDA submission to the NMPA.

Furthermore, the “Hong Kong and Macau Medicine and Equipment Connect” policy enabled the drug's use in designated hospitals in the Greater Bay Area after it gained approval in Hong Kong and Macau. These interconnected policies effectively create a multi-pronged fast track, reducing the notorious lag time that once separated Chinese patients from global medical breakthroughs. The successful navigation of these pathways by CMS serves as a powerful case study for other global pharmaceutical firms looking to enter the dynamic Chinese market.

The Road Ahead: Expanding Horizons

While the vitiligo approval is a monumental achievement, it may be just the beginning for ruxolitinib phosphate cream in China. The product is also approved in the United States for the treatment of mild to moderate atopic dermatitis (AD), another chronic inflammatory skin condition that affects a large patient population.

CMS has already announced that its Phase III clinical trial of the cream for atopic dermatitis in China has yielded positive results. The company is now actively advancing the NDA for this second indication. If approved, it would provide a new, non-steroidal topical option for millions of AD patients in China and further solidify Dermavon’s leadership position in the nation's rapidly expanding dermatology market.